Can Targeting the Actin Cytoskeleton be a Therapeutic Strategy?
Given the central role of the actin cytoskeleton in cancer progression, targeting its regulatory mechanisms presents a potential therapeutic strategy. Inhibitors of Rho GTPases, actin polymerization, and actin-binding proteins are being explored to disrupt cancer cell motility and invasion, aiming to limit metastasis and improve clinical outcomes.
